Increasing Search for New Drugs for Medical Problems Increases Fragment-Based Drug Discovery Market

The increasing search for new drugs to treat complicated medical problems has led to a surge in the global fragment-based drug discovery market. Furthermore, the growth of the global fragment-based drug discovery market has also led to dominance of biopharmaceutical companies, as the market requires a system for identification of lead compounds in the process of drug discovery.

Browse the Complete Report Details at: http://www.transparencymarketresearch.com/fragment-based-drug-discovery-market.html

38.4% of the global fragment-based drug discovery market was collectively held by its top three players in 2014. Astex Pharmaceuticals, Charles River Laboratories International, Inc., and Sygnature Discovery were the key contributors to the market revenue at the time and are expected to retain their lead in the near future. A new research report released by Transparency Market Research states that with 52.3% of the global fragment-based drug discovery market occupied by regional players, this highly fragmented market is dominated by local market companies that offer cheaper services.

The significantly large presence of regional companies is leaving the market in an unorganized state which makes it difficult for prominent players to expand their horizons. The TMR report also states that the threat of new entrants to the market is expected to remain moderate in the coming years, due to a high setup cost and the need for skilled professionals for the programs. Additionally, the market is governed by extremely strict regulations created by bodies such as the FDA and the EMA, further reducing the scope of new entrants into the market.

In this research study, the global fragment-based drug discovery market has been evaluated on the basis of the service component and end user. Based on service component, the market is broadly segmented into fragment screening and fragment optimization. Of these, the fragment screening segment occupied the leading position in 2014.

The report further classifies this segment into biophysical techniques and non-biophysical techniques. The biophysical techniques segment is then categorized into differential scanning fluorimetry (DSF) assay (Thermal Shift), nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography, isothermal titration calorimetry (ITC), fluorescence polarization (FP), biolayer interferometry, surface plasmon resonance, capillary electrophoresis, mass spectrometry, and biochemical assays.

Biopharmaceutical companies, academic and research institutions, and CROs are the major end users of fragment-based drugs discovery services. In 2014, biopharmaceutical companies emerged as the biggest fragment-based drugs discovery services user and held a share of 46% in the overall market.

The report also analyzes the global market for fragment-based drug discoveries on the basis of its regional segmentation. According to the report, North America led the global market in 2014. The presence of pharmaceutical companies in a large number in the U.S. was the main factor behind the dominance of North America among all the regional markets for fragment-based drug discoveries including Latin America, Europe, Asia Pacific, and the Rest of the World.

The increasing research and development activities for fragment-based drug discoveries are projected to drive the North America fragment-based drug discovery market in the coming years, states the research report. However, analysts expect the fragment-based drug discovery market in Asia Pacific to exhibit the highest growth over the forecast period.

The rise in research and development activities for drug discovery in various emerging nations in Asia, together with the increasing demand for advanced medical and healthcare infrastructure, is likely to drive the growth of the Asia Pacific market for fragment-based drug discoveries, notes the study.

Obtain the Sample PDF containing the Upcoming Opportunities and Growth Factors for this Market at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4741

The global fragment-based drug discovery market is highly fragmented in nature, states the research report. Sygnature Discovery, Kinetic Discovery Ltd., Emerald BioStructures Inc., Evotec AG, Crown Bioscience Inc., Sprint Bioscience, Beactica AB, Astex Pharmaceuticals, Proteros Fragments GmbH, Charles River Laboratories International Inc., Structure Based Design Inc., and Alveus Pharmaceuticals Pvt. Ltd. are the major market participants mentioned in this study.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/